View clinical trials related to Rheumatoid Arthritis.
Filter by:Multicenter, randomized, double-blind, placebo-controlled, 5-arm, dose-ranging study to assess the efficacy of subcutaneous injections of Golimumab (CNTO 148), 50 or 100 mg, at either 2- or 4- week intervals in subjects with active RA despite MTX therapy.
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.
The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.
To compare the effects of the combination of ETN and MTX to MTX alone on radiographic change and clinical disease activity in subjects with early RA over 12 months.
The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s regulation. 1. Unknown adverse reactions, especially serious adverse reactions 2. Incidences of adverse reactions under routine drug uses 3. Factors that may affect the safety of the drug 4. Factors that may affect the efficacy of the drug This investigation spanned 3 different studies, 0881A-101575 (alias B1801105) NCT00195403, 0881A-102018 (alias B1801112) NCT00195416 and 0881A-102212 (alias B1801113). All studies have been combined into this record.
The purpose of this study is to evaluate long-term safety of etanercept in patients with rheumatoid arthritis who successfully have completed open-label safety study 0881A1-301-EU
The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.
Computers allow individuals to engage in economic, social, and entertainment activities. Despite the many benefits of computer use, many individuals with rheumatic diseases may have difficulty using a computer. However, currently there is almost no information on the problems individuals with rheumatic diseases experience using a computer. Baseline information on the types of problems experienced by individuals with rheumatic diseases as well as the magnitude of those problems is needed before methods can be developed to intervene and remediate them. In this study we will develop and administer to a representative sample of patients with rheumatic diseases a survey which will examine the type and magnitude of computer problems experienced by those with rheumatic diseases. The goal of this study is to complete a needs assessment on the problems experienced by those with rheumatic diseases during computer use. This assessment will lay the groundwork for the development of outcome measures and interventions to improve computer use for individuals with rheumatic diseases. In the future it will assist individuals with rheumatic diseases to be able to use computers more comfortably and efficiently.
An open ended study in which patients who completed the double-blind study CDP870-027 [NCT00152386] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).